Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 5/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694779 | 1.00 | MAOA (0.43) | MAOATMEM97SIGMAR1HTR6F10 | |
| SCHEMBL3042951 | 0.89 | TMEM97 (0.37) | TMEM97SIGMAR1HTR6F10HDAC6 | |
| SCHEMBL3043362 | 0.87 | MAOA (0.46) | MAOAHTR6F10 | |
| SCHEMBL5795451 | 0.87 | MAOA (0.46) | MAOAHTR6F10 | |
| SCHEMBL3039459 | 0.82 | MAOA (0.45) | MAOAHTR6F10 | |
| SCHEMBL3046390 | 0.78 | F10 (0.39) | MAOAHTR6F10 | |
| SCHEMBL14334714 | 0.76 | MAOA (0.47) | MAOATMEM97SIGMAR1HTR6F10 | |
| SCHEMBL14334493 | 0.76 | F10 (0.45) | MAOATMEM97SIGMAR1HTR6F10 | |
| SCHEMBL6040312 | 0.75 | MAOA (0.54) | MAOAF10 | |
| SCHEMBL14334647 | 0.74 | HTR6 (0.62) | MAOAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478629-B1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN CO LLC (US) | 2006-10-11 | — | — | EP | claimed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | claimed |
| EP-1478629-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | claimed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | claimed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1478629-B1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN CO LLC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1478629-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885TMEM97 3290/4885SIGMAR1 1597/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885TMEM97 3290/4885SIGMAR1 1597/4885 |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885TMEM97 3290/4885SIGMAR1 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.